The Prostate Centre Database (PCDB) has become one of the largest and most comprehensive databases specific to prostate cancer (PC) since its development in 2003. The PCDB now includes over 12,000 unique patient records with each record housing 365 fields to collect comprehensive data covering the spectrum of medical, psychosocial, quality of life, and exercise care offered to our patients.
Over the past 5 years, follow up for long-term results has exceeded 85% of all patients. This data offers a unique perspective on the effectiveness of our treatments and a clearer long-term linear view of the clinical outcomes of our patients. One of the unique elements of the Prostate Centre Database is the effort we devote to the collection of data related to treatment outcomes.
Our wide-spectrum data collection includes inquiries regarding the patient’s experience of fatigue/energy, sexual, urinary, and bowel functions, pain, and emotional wellbeing. The importance of this data, beyond recognition of treatment-side-effect profiles, is that it informs the type of post-treatment survivorship programming required to ensure the highest possible post-treatment quality of life.
The database is designed to be a springboard for a multitude of clinical research questions. Initial investigations focused on questions related to survival, and outcomes pre and post-treatment. More recently there have been several queries examining the quality of life of patients following surgery. For example, analysis of data from the Prostate Centre Database reveals that patients often fail to return to baseline in the following quality of life domains: Sexual Function, Sexual Desire, Bladder Control and Energy. Moreover, our research, along with the international scientific literature, suggests that the majority of patients experience significant psychosocial distress specific to these losses in quality of life.
The combined results of these types of analyses allow us to better understand and inform patients about the likely impact of treatment on survival and quality of life. As our knowledge of the disease and treatments continues to grow we will be able to increasingly provide personlized care through complex disease classification, combined with least invasive treatment recommendations. This process has already helped to set us apart as a leader in quality of care.
One of the unique elements of the database is the significance placed on the collection of data related to treatment outcomes. The importance of this data, beyond recognition of treatment side-effects, is that it informs the type of survivorship programming required to ensure the highest post-treatment quality of life possible.
It is this outcome data that has directly resulted in the development of the Prostate Cancer Rehabilitation Clinic for sexual and urinary health; the Survivorship Exercise Program for challenging fatigue; and the Psychosocial Support Program to help patients, couples and families adapt to the chronic side-effects of PC treatment. As a result, the Prostate Centre offers one of the most sophisticaed survivorship programs available to patients of any cancer diagnosis (e.g. breast, colon) at The Princess Margaret.
Overall, the development of the PCDB will enable us to further personalize care for our patients while making important contributions to the international community through research and education.